Search results for "BODIES"

showing 10 items of 2217 documents

Three years of experience : the Italian registry and safety data update

2011

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability…

AdultMalemedicine.medical_specialtyPediatricsMultiple SclerosisDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingmedicineHumansRegistriesAdverse effectbusiness.industryNatalizumabMultiple sclerosisGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYsurveillance program; pharmacovigilance; multiple sclerosis; natalizumabPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessMultiple sclerosis NatalizumabSurveillance program Pharmacovigilancemedicine.drug
researchProduct

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

2009

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients t…

AdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisPatient DropoutsDatabases FactualAlternative medicineDermatologyPharmacologyAntibodies Monoclonal HumanizedNatalizumabPharmacovigilanceProduct Surveillance PostmarketingMedicineHumansGlatiramer acetateMultiple sclerosis NatalizumabSurveillance programPharmacovigilancebusiness.industryMultiple sclerosisNatalizumabAntibodies MonoclonalDrug agencyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPsychiatry and Mental healthItalyPHARMACOVIGILANCEREGISTRYSettore MED/26 - NeurologiaFemaleNeurology (clinical)Neurosurgerybusinessmedicine.drugFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia.

1995

Aplastic anemia is occasionally caused by viral hepatitis, hepatitis C virus being the most important factor. Pathogenetically, decreased bone marrow function, abnormalities of the bone marrow microenvironment, and immune-mediated suppression of hematopoiesis are important. Hepatitis C virus infection is associated with a variety of extrahepatic manifestations including autoimmune features like cryoglobulinemia, Sjogren's syndrome, and autoimmune hepatitis. Here we report the case of a 42-year-old man with aplastic anemia due to posttransfusional hepatitis C virus infection associated with cryoglobulinemia and LKM-1 autoantibodies. Following a triple immunosuppressive therapy, there was a c…

AdultMalemedicine.medical_specialtyPhysiologyHepatitis C virusAutoimmune hepatitismedicine.disease_causeBone MarrowInternal medicinemedicineHumansAplastic anemiaAutoantibodiesbusiness.industryGastroenterologyAutoantibodyAnemia AplasticTransfusion ReactionHepatologymedicine.diseaseVirologyCryoglobulinemiaHepatitis Cmedicine.anatomical_structureCryoglobulinemiaImmunologyBone marrowbusinessViral hepatitisDigestive diseases and sciences
researchProduct

Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily.

2009

The virus that causes Kaposi sarcoma, KS-associated herpesvirus (KSHV, also known as human herpesvirus 8) has an unusual distribution and poorly characterized modes of transmission. To clarify these issues, socio-demographic correlates of KSHV seroprevalence were examined in a population-based study. In 1,154 randomly sampled adults (aged 32- 92, mean 71 years) throughout Sicily, KSHV antibodies were detected with four assays and a conservative algorithm. Seroprevalence was re-weighted to the population. Odds ratios with 95% confidence intervals (OR, CI) from multivariate logistic regression were used to estimate associations of seroprevalence with interview data. KSHV seroprevalence was 8.…

AdultMalemedicine.medical_specialtyPopulationLogistic regressionAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataArticleSerologyRisk FactorsSeroepidemiologic StudiesVirologyEpidemiologymedicineSeroprevalenceGammaherpesvirinaeHumanseducationSicilyAgedAged 80 and overeducation.field_of_studybiologybusiness.industryOdds ratioHerpesviridae InfectionsMiddle Agedbiology.organism_classificationVirologyKSHV seroprevalence socio-economic correlates elderly SicilyConfidence intervalInfectious DiseasesSocioeconomic FactorsHerpesvirus 8 HumanFemalebusiness
researchProduct

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

2018

Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites in Canada, Europe, Jordan, and the United States. Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients assigned to lanadelumab were further randomized 1:1:1 to 1 of the 3 dose regimens. Patients 12 years or older with hereditary a…

AdultMalemedicine.medical_specialtyRandomizationAdolescentInjections SubcutaneousLanadelumabPlaceboAntibodies Monoclonal Humanizedlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumans030212 general & internal medicineYoung adultAdverse effectChildPlasma KallikreinAgedHereditary Angioedema Types I and IIbusiness.industryAntibodies MonoclonalCorrectionGeneral MedicineMiddle Agedmedicine.diseaseClinical trial030228 respiratory systemHereditary angioedemaQuality of LifeFemalebusinessJAMA
researchProduct

Deterioration in quality of life (QOL) in patients with malignant ascites : Results from a phase II/III study comparing paracentesis plus catumaxomab…

2012

Background: Malignant ascites (MA) is associated with poor prognosis and limited palliative therapeutic options. Therefore, quality of life (QoL) assessment is of particular importance to demonstrate new treatment value. Following the demonstration of the superiority of catumaxomab and paracentesis over paracentesis on puncture-free survival, this analysis aimed at comparing deterioration in QoL between both the treatment options. Patients and methods: In a randomised, multicentre, phase II/III study of patients with MA due to epithelial cell adhesion molecule (EpCAM) positive cancer, the QoL was evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life …

AdultMalemedicine.medical_specialtyRandomizationPalliative careCatumaxomabMedizinlaw.inventionYoung AdultQuality of lifeRandomized controlled triallawAntigens NeoplasmNeoplasmsAscitesAntibodies BispecificmedicineParacentesisHumansParacentesisdeteriorationAgedProportional Hazards ModelsAged 80 and overOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryAscitesmalignant ascitesHematologyOriginal ArticlesMiddle AgedEpithelial Cell Adhesion MoleculeCombined Modality TherapyhumanitiesSurgeryClinical trialOncologyquality of lifeQuality of Life and Supportive CareFemalemedicine.symptombusinessCell Adhesion Moleculesmedicine.drug
researchProduct

Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of maligna…

2020

AdultMalemedicine.medical_specialtyRisk of malignancyMEDLINEDermatologyRisk AssessmentDermatomyositisNecrosisRisk FactorsNeoplasmsmedicineHumansMuscle SkeletalAgedAutoantibodiesRetrospective StudiesSkinbusiness.industryIncidenceNecrotizing myositisRetrospective cohort studyExanthemaMiddle AgedDermatomyositisPrognosismedicine.diseaseDermatologyRashFemalemedicine.symptombusinessMi-2 Nucleosome Remodeling and Deacetylase ComplexJournal of the American Academy of Dermatology
researchProduct

Retrospective analysis of management of ingested foreign bodies and food impactions in emergency endoscopic setting in adults.

2016

Background: Ingestion of foreign bodies and food impaction represent the second most common endoscopic emergency after bleeding. The aim of this paper is to report the management and the outcomes in 67 patients admitted for suspected ingestion of foreign body between December 2012 and December 2014. Methods: This retrospective study was conducted at Palermo University Hospitals, Italy, over a 2-year period. We reviewed patients’ database (age, sex, type of foreign body and its anatomical location, treatments, and outcomes as complications, success rates, and mortalities). Results: Foreign bodies were found in all of our 67 patients. Almost all were found in the stomach and lower esophagus (…

AdultMalemedicine.medical_specialtySedationAchalasiaEndoscopy GastrointestinalHospitals University03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRisk FactorsmedicineIngestionHumansFood bolus impactionRetrospective StudiesEndoscopic managementEsophageal diseasebusiness.industryStomachAge FactorsEndoscopic management; Food bolus impaction; Foreign body; Upper endoscopyRetrospective cohort studyMiddle Agedmedicine.diseaseForeign BodiesEndoscopic ProcedureSurgerySettore MED/18 - Chirurgia GeneraleForeign bodymedicine.anatomical_structureItalyUpper endoscopyFood030220 oncology & carcinogenesisEmergency Medicine030211 gastroenterology & hepatologyFemalemedicine.symptomForeign bodyEmergenciesbusinessResearch ArticleBMC emergency medicine
researchProduct

High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.

2018

AbstractContextSerum TSH receptor autoantibody (TSH-R-Ab) is a biomarker of Graves disease (GD). Studies have shown that the levels of this TSH-R-Ab have clinical significance.ObjectiveTo differentiate between thyroidal GD only and Graves orbitopathy (GD + GO).DesignControlled, follow-up study.SettingAcademic tertiary referral center for GD + GO.SubjectsSixty patients with GD, GD + GO, and controls.InterventionSerial serum dilution analyses with six automated, ELISA, and cell-based assays for TSH-R-Ab.Main Outcome MeasureDifferentiation among GD phenotypes.ResultsAll undiluted samples of hyperthyroid-untreated GD patients were positive with the six assays but became negative at dilution 1:9…

AdultMalemedicine.medical_specialtySerial dilutionEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)BiochemistryThyrotropin receptorDiagnosis Differential03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyAntithyroid AgentsInternal medicineMedicineHumansEuthyroidAgedAutoantibodiesMethimazolebiologybusiness.industryBiochemistry (medical)AutoantibodyReceptors ThyrotropinMiddle Agedmedicine.diseasePrognosisGraves DiseaseGraves OphthalmopathyTiterEndocrinology030220 oncology & carcinogenesisbiology.proteinFemaleAntibodybusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct